"Follana, Philippe" - Selaus tekijän mukaan TUNICRIS-julkaisut
Viitteet 1-2 / 2
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo : Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
(2024)
articleObjective: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. Methods: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) ... -
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
(01.07.2024)
articleOBJECTIVE: To identify characteristics associated with long-term progression-free survival (≥2 years) in patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in the phase III ...
